Conference Overview & Objectives

Alfred K. Cheung
University of Utah

Johannes Mann
Friedrich Alexander
University of Erlangen
Disclosure of Interests

Alfred K. Cheung
• NIH (SPRINT trial investigator)
• Boehringer-Ingelheim (consultancy)
• UptoDate (contributor)
• JASN (interim Co-EIC)

Johannes Mann
• EU (group grant)
• UptoDate (contributor)
• Novo Nordisk, Boehringer, Bayer, Fresenius, Roche, Sanofi (consultancy)
Objectives

• Explore which areas in the 2012 KDIGO Guidelines on BP management in CKD-ND need revisiting in next guideline update and which areas do not

KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease

VOLUME 2 | ISSUE 5 | DECEMBER 2012
http://www.kidney INTERNATIONAL.ORG

• Identify key issues, controversial areas and current knowledge relevant to optimal management of hypertension in patients with CKD-ND
Scope of This Conference

• Focus on
  – CKD-ND (infer from general population as appropriate)
  – BP (not other cardiovascular therapies)
Multiple outcomes
Kidney, heart, others

In CKD-ND
Scope of This Conference

• Focus on
  – CKD-ND (infer from general population as appropriate)
  – BP (not other cardiovascular therapies)

• Public input on conference scope of work

• 4 breakout groups with
  – topics specified by Conference Steering Committee
  – questions for each group pre-defined by Group Co-chairs
  – scoping review was performed by Cochrane Kidney Transplantation to identify new publications relevant to guideline and conference topics/issues
  – key publications have also been proposed by Group Co-chairs
4 Breakout Groups

- **Group 1: BP Measurement**
  Moderators: Tara Chang & Mark Sarnak

- **Group 2: Management of HTN in CKD patients in general and in those with DM**
  Moderators: Vlado Perkovic & Charles Tomson

- **Group 3: Management of HTN in CKD among elderly and individuals with previous stroke**
  Moderators: William Cushman & Roberto Pecoits-Filho

- **Group 4: Management of HTN in CKD in transplant and pediatric populations**
  Moderators: Joachim Ix & Sheldon Tobe

*Preliminary (Saturday) and Final (Sunday) Group reports and discussions*
5 Plenary Lectures

Objectives: Stimulate discussion; not comprehensive

- Salt intake and BP (Friedrich Luft)
- BP Measurement & variability in CKD (George Stergiou)
- Choice of agents and interventional therapies for HTN in CKD (Robert Toto)
- Adverse effects from intensive BP lowering on kidney function (George Bakris)
- Intensive BP lowering: Risks and benefits in elderly and effects on cognitive function (Jeff Williamson)
Deliverables

• Proceedings will be published as a conference report in a nephrology journal

• Conference will provide roadmap for planning of update of KDIGO guideline on BP management in CKD (process to begin in 2018)
Goals of breakout sessions

• Address all assigned questions (so make sure adequate time is allocated for each!)
• Develop consensus when possible but if not, state so explicitly
• Peruse BP guideline recommendations and designate which ones require revisiting by the next guideline updating Work Group
• Identify research/knowledge gaps and provide research recommendations